Kochiadakis 2004b.

Methods	RCT Single‐blind Loss to follow‐up reported: no
Participants	Any documented symptomatic previous or persistent AF. Type: paroxysmal or recent onset 59%, persistent 41% (mean duration: 8 months). n = 254 Men: 50% Age (mean): 63 (SD 10) years Structural heart disease: 41%. LAD: 44 mm. LVEF: 53%
Interventions	Propafenone 450 mg/day vs sotalol 300 mg/day vs placebo Method of AF cardioversion: both pharmacological and electrical, % NS Warfarin discretionary
Outcomes	At 12 and 24 months: Mortality Proarrhythmia Adverse effects AF recurrence
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of randomisation not described.
Allocation concealment (selection bias)	Unclear risk	Method of concealment not described.
Blinding (performance bias and detection bias) All outcomes	High risk	Single‐blind study.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Lost to follow‐up are not clearly described.
Selective reporting (reporting bias)	Low risk	All prespecified outcomes were reported in the prespecified way. All expected outcomes of interest were reported.
Other bias	Low risk	No other bias apparent.